phycoerythrin pe labeled mouse anti human cd30 antibodies  (Miltenyi Biotec)

Journal: Cancer Chemotherapy and Pharmacology

Article Title: The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis

doi: 10.1007/s00280-023-04609-5

Figure Lengend Snippet: HH cells abundantly express CD30 and the viability is reduced after BV treatment. a Cell viabilities following treatment with BV (0.0068–68 nM) for 72 h. b Flow cytometry histograms. Cells were sorted following staining with PE-conjugated anti-CD30 antibodies (orange), with isotype-matched control antibodies (blue), or without antibodies (red). BV brentuximab vedotin, PE phycoerythrin

Article Snippet: Cells were collected and incubated for 30 min at 4 °C with phycoerythrin (PE)-labeled mouse anti-human CD30 antibodies (#130-098-686, Miltenyi Biotec, Bergisch Gladbach, Germany), with isotype-matched control antibodies (#130-092-213, Miltenyi Biotec), or without antibodies.

Techniques: Flow Cytometry, Staining, Control

Journal: Aesthetic surgery journal

Article Title: IL-9 Is a Biomarker of BIA-ALCL Detected Rapidly by Lateral Flow Assay.

doi: 10.1093/asj/sjae137

Figure Lengend Snippet: Figure 3. CD30 lateral flow assay. (A) CD30 standards were diluted from 0 to 10 ng/mL in a benign seroma. (B) Correlation of CD30 concentration with TL/CL ratio (r2 = 0.72, y = 0.05x + 0.7, P = .02). (C) Comparison of CD30 in benign and ALCL seromas (benign, 0.198 ± 0.036 [n = 15] vs ALCL, 0.779 ± 0.083 [n = 11]; P < .0001, t-test). CL, control line; TL, test line.

Article Snippet: Similarly, CD30 LFA strips were made by striping mouse anti-CD30 antibody (R&D Systems, catalog number MAB2291).

Techniques: Lateral Flow Assay, Concentration Assay, Comparison, Control

Journal: Molecular Therapy Oncolytics

Article Title: Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment

doi: 10.1016/j.omto.2023.07.007

Figure Lengend Snippet: Construction of the Nb phage library and screening of anti-CD30 Nbs and anti-CD5 Nbs (A) Schematic of construction of the Nb phage library and screening of Nbs. (B) The variable domain of heavy chain of heavy-chain antibody (VHH) genes were obtained by two-step PCR, and the library size was measured by counting the colonies after serial dilution (M, DNA marker; 1, PCR product). (C) Monoclonal phage ELISA. 24 positive phages from the three rounds of panning were tested for binding affinity by ELISA with CD30- and CD5-coated plates. (D) Flow cytometry screening of monoclonal phages capable of binding to cells. Karpas-299 cells were used as target cells to validate positive monoclonal phages by flow cytometry. Negative control (NC) phages that did not express Nbs were used as a negative control.

Article Snippet: For target antigens staining, the following antibodies were used: mouse anti-human PE-CD30 (BD Biosciences, 550041) and mouse anti-human Brilliant Violet 421-CD5 (BD Biosciences, 562646).

Techniques: Serial Dilution, Marker, Enzyme-linked Immunosorbent Assay, Binding Assay, Flow Cytometry, Negative Control

Journal: Molecular Therapy Oncolytics

Article Title: Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment

doi: 10.1016/j.omto.2023.07.007

Figure Lengend Snippet: In vitro binding ability validation of the screened Nbs (A) The biding affinity of Nb-Fc to CD30 or CD5 was measured by ELISA. (B) Three anti-CD30 Nbs and four anti-CD5 Nbs were selected, and we performed ELISA at the indicated dilution ratios by incubation with the corresponding antigens. Fc served as negative control. (C) Detection of the binding affinity of the Nb-Fc or scFv-Fc antibodies to CD5 or CD30, respectively, by ELISA. (D) Single-target NbCD30 or NbCD5-CAR-T cells were co-cultured with Karpas-299 cells (CD30 + CD5 + ) at different effector-to-target ratios for 24 h, and the specific cytotoxicity was determined by Lactic Dehydrogenase (LDH) assay. ∗∗∗∗p < 0.0001 for one-way ANOVA with multiple-comparisons test. All data are mean ± standard error.

Article Snippet: For target antigens staining, the following antibodies were used: mouse anti-human PE-CD30 (BD Biosciences, 550041) and mouse anti-human Brilliant Violet 421-CD5 (BD Biosciences, 562646).

Techniques: In Vitro, Binding Assay, Enzyme-linked Immunosorbent Assay, Incubation, Negative Control, Cell Culture, Lactate Dehydrogenase Assay

Journal: Molecular Therapy Oncolytics

Article Title: Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment

doi: 10.1016/j.omto.2023.07.007

Figure Lengend Snippet: The binding ability was predicted by molecular docking and verified by SPR experiments (A) Molecular docking prediction model of anti-CD30/CD5 Nbs or scFv to corresponding antigens. The light blue structure indicates the antigen, the dark blue structure indicates the antibody, the interface area (red) indicates the region of the two proteins in contact with each other, and ΔG indicates the free energy of binding. (B) SPR experiments were performed to measure the binding affinity of Nb-Fc or scFv-Fc on its corresponding antigen.

Article Snippet: For target antigens staining, the following antibodies were used: mouse anti-human PE-CD30 (BD Biosciences, 550041) and mouse anti-human Brilliant Violet 421-CD5 (BD Biosciences, 562646).

Techniques: Binding Assay

Journal: Molecular Therapy Oncolytics

Article Title: Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment

doi: 10.1016/j.omto.2023.07.007

Figure Lengend Snippet: Construction of bispecific Nb/scFv-derived CAR-T cells to verify in vitro function (A) Schematic of CAR structure and single- or bispecific scFv-CAR. (B) Schematic of single NbCD30/NbCD5-CAR or bispecific NbCD30-CD5-CAR. (C) Single-or bispecific scFv-CAR-T cells were co-cultured with Karpas-299 cells (CD30 + CD5 + ) or SupT1 cells (CD30 + CD5 − ) at the indicated E:T ratios for 24 h, and the specific cytotoxicity was determined by LDH assay. The data shown are representative results of three independent replication experiments. (D) Single-or bispecific Nb-CAR-T cells were co-cultured with Karpas-299 cells (CD30 + CD5 + ) or SupT1 cells (CD30 + CD5 − ) at different E:T ratios for 24 h, and the specific cytotoxicity was determined by LDH assay. The data shown are representative results of three independent replication experiments. (E) Bispecific Nb-CAR-T and scFv-CAR-T cells were co-cultured with Karpas-299 cells (CD30 + CD5 + ) or Raji cells (CD30 − CD5 − ) at different E:T ratios for 24 h, and the specific cytotoxicity was determined by LDH assay. (F) NbCD30/CD5-CAR-T cells or mock T cells (untransduced T cells) were incubated with tumor target cells (Karpas-299) for 24 h. The levels of IFN-γ, TNF-α, IL-2, and granzyme B in culture supernatants were measured by ELISA. (G) CAR-T cells or control T cells were incubated with tumor target cells (Karpas-299) at a 1:1 ratio for 24 h. Secretion of IFN-γ was measured by ELISpot assay. All data are representative of three independent replication experiments. All data are mean ± standard error; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 for one-way ANOVA.

Article Snippet: For target antigens staining, the following antibodies were used: mouse anti-human PE-CD30 (BD Biosciences, 550041) and mouse anti-human Brilliant Violet 421-CD5 (BD Biosciences, 562646).

Techniques: Derivative Assay, In Vitro, Cell Culture, Lactate Dehydrogenase Assay, Incubation, Enzyme-linked Immunosorbent Assay, Enzyme-linked Immunospot

Journal: Molecular Therapy Oncolytics

Article Title: Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment

doi: 10.1016/j.omto.2023.07.007

Figure Lengend Snippet: Bispecific CD30-CD5-CAR-T cells are more effective for tumor growth suppression (A and B) 6 × 10 6 Karpas-299 cells were inoculated subcutaneously into NCG mice. The tumor reached 100 mm 3 after 7–10 days. Various T cells were infused via tail vein injection. Tumor engraftment was monitored every 2–3 days (1–2 μg of human IL-2 per mouse was injected at a frequency of 2–3 days). s.c., subcutaneous; i.v., intravenous; i.p., intraperitoneal. Tumor volumes were monitored after injection of CAR-T cells (scale bar, 10 mm). (C) The tumor mass was quantified. All data are mean ± standard error; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 for one-way ANOVA.

Article Snippet: For target antigens staining, the following antibodies were used: mouse anti-human PE-CD30 (BD Biosciences, 550041) and mouse anti-human Brilliant Violet 421-CD5 (BD Biosciences, 562646).

Techniques: Injection

Journal: Molecular Therapy Oncolytics

Article Title: Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment

doi: 10.1016/j.omto.2023.07.007

Figure Lengend Snippet: Nb-derived CD30 and CD5 bispecific CAR-T cells enhanced anti-tumor potency in vivo (A) Fluorescence-activated cell sorting (FACS) analysis shows the proportion of tumor-infiltrating CAR-T cells and cytokine production capacity. (B) Immunofluorescence staining of tumor tissue sections. The tumor tissue sections were analyzed for immunofluorescence by staining with anti-human CD8 (red), anti-human IFN-γ (green), and anti-human granzyme B (pink) antibodies, and the nuclei were stained with DAPI (blue). The statistical plot shows the mean fluorescence intensity statistics for CD8, IFN-γ, and granzyme B expressed as the mean ± SD from three randomly selected fields of thin tumor sections. Scale bar, 20 μm. (C) Survival curve of mice after tumor inoculation and then injection of the indicated CAR-T cells. ∗p < 0.05, ∗∗p < 0.01, log rank Mantel-Cox test. All data are mean ± standard error; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, one-way ANOVA.

Article Snippet: For target antigens staining, the following antibodies were used: mouse anti-human PE-CD30 (BD Biosciences, 550041) and mouse anti-human Brilliant Violet 421-CD5 (BD Biosciences, 562646).

Techniques: Derivative Assay, In Vivo, Fluorescence, FACS, Immunofluorescence, Staining, Injection

Journal: Retrovirology

Article Title: Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-κB activation

doi: 10.1186/1742-4690-2-29

Figure Lengend Snippet: NF-κB activators isolated from the TL-OmI cDNA library.

Article Snippet: The following antibodies were used: PE-labeled mouse anti-human CD4 and CD25, FITC-labeled anti CD3 and CD8 (BD Biosciences Pharmingen, San Diego, CA); and PE-labeled mouse anti-human CD30 (Dako Corporation, Carpinteria, CA or Immunotech, Marseille, France).

Techniques: Isolation

Journal: Retrovirology

Article Title: Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-κB activation

doi: 10.1186/1742-4690-2-29

Figure Lengend Snippet: Exogenous stable expression of CD30 induces constitutive NF-κB activation in Rat-1 cells Rat-1 κB- bsr EGFPx2 cells were infected with the pMX kBL1, pMX kBL1Δ Bgl II, or pMX CD30WT virus and tested for the expression of EGFP by FACS analysis. The cells infected with pMX virus were used as a negative control. CD30 expression was seen in cells infected with all three viruses containing CD30 gene (pMX kBL1, pMX kBL1Δ Bgl II, pMX CD30WT) but not pMX virus (data not shown).

Article Snippet: The following antibodies were used: PE-labeled mouse anti-human CD4 and CD25, FITC-labeled anti CD3 and CD8 (BD Biosciences Pharmingen, San Diego, CA); and PE-labeled mouse anti-human CD30 (Dako Corporation, Carpinteria, CA or Immunotech, Marseille, France).

Techniques: Expressing, Activation Assay, Infection, Negative Control

Journal: Retrovirology

Article Title: Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-κB activation

doi: 10.1186/1742-4690-2-29

Figure Lengend Snippet: Elevated expression of CD30 in ATL cell lines . CD30 expression was examined in A) ATL, B) HTLV-1-transformed, and C) HTLV-1-negative cell lines by FACS analysis. A Burkitt lymphoma cell line (BJAB) was used as a negative control in A). TL-OmI was used as a standard for the CD30 expression level in B) and C).

Article Snippet: The following antibodies were used: PE-labeled mouse anti-human CD4 and CD25, FITC-labeled anti CD3 and CD8 (BD Biosciences Pharmingen, San Diego, CA); and PE-labeled mouse anti-human CD30 (Dako Corporation, Carpinteria, CA or Immunotech, Marseille, France).

Techniques: Expressing, Transformation Assay, Negative Control

Journal: Retrovirology

Article Title: Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-κB activation

doi: 10.1186/1742-4690-2-29

Figure Lengend Snippet: CD30 expression in primary ATL cells . A) Primary ATL cells from a patient (case 8) were tested for the expression of CD3, CD4, CD8, CD25 and CD30 by FACS analysis. B) Summary of the number of CD30-positive ATL cases.

Article Snippet: The following antibodies were used: PE-labeled mouse anti-human CD4 and CD25, FITC-labeled anti CD3 and CD8 (BD Biosciences Pharmingen, San Diego, CA); and PE-labeled mouse anti-human CD30 (Dako Corporation, Carpinteria, CA or Immunotech, Marseille, France).

Techniques: Expressing

Journal: Retrovirology

Article Title: Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-κB activation

doi: 10.1186/1742-4690-2-29

Figure Lengend Snippet: Cell surface markers in CD30-positive ATL cases

Article Snippet: The following antibodies were used: PE-labeled mouse anti-human CD4 and CD25, FITC-labeled anti CD3 and CD8 (BD Biosciences Pharmingen, San Diego, CA); and PE-labeled mouse anti-human CD30 (Dako Corporation, Carpinteria, CA or Immunotech, Marseille, France).

Techniques:

Journal: Retrovirology

Article Title: Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-κB activation

doi: 10.1186/1742-4690-2-29

Figure Lengend Snippet: CD30 mRNA expression in primary ATL cells Primary ATL cells from ATL patients (lanes 5–12) and normal PBLs from healthy adult donors (lanes 1–3) were tested for CD30 (upper panel) and β-actin (lower panel) mRNA expression by RT-PCR analysis. The CD30 expression was seen in ATL8 (lane 12). PHA-stimulated PBLs (lane 4) and HUT-102 (lane 13) were used as a positive control.

Article Snippet: The following antibodies were used: PE-labeled mouse anti-human CD4 and CD25, FITC-labeled anti CD3 and CD8 (BD Biosciences Pharmingen, San Diego, CA); and PE-labeled mouse anti-human CD30 (Dako Corporation, Carpinteria, CA or Immunotech, Marseille, France).

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Positive Control

Journal: Molecular Vision

Article Title: Study of the expression of CD30 in pterygia compared to healthy conjunctivas

doi:

Figure Lengend Snippet: Immunohistochemistry for CD30 and Ki-67. Reed-Sternberg cells are positive for CD30 identified in Hodgkin’s disease ( A ). Nuclear expression of Ki-67 identified in human tonsils ( B ). Both slides were counterstained with Mayer’s hematoxylin (400×).

Article Snippet: Primary antibodies were the ready-to-use mouse anti-human CD30 monoclonal antibody (Dako, Glostrup, Denmark) and the mouse anti-human Ki-67 monoclonal antibody (Biocare Medical, Concord, CA) diluted at 1:50; both primary antibodies were incubated at room temperature (RT) for 30 min.

Techniques: Immunohistochemistry, Expressing

Journal: Molecular Vision

Article Title: Study of the expression of CD30 in pterygia compared to healthy conjunctivas

doi:

Figure Lengend Snippet: Hematoxylin and eosin staining for healthy conjunctiva ( A ) and pterygium ( C ) and immunoreactivity for CD30 in healthy conjunctiva ( B ) and pterygium ( D ). The arrow indicates the strong immunoreactivity in the basal epithelium (400×).

Article Snippet: Primary antibodies were the ready-to-use mouse anti-human CD30 monoclonal antibody (Dako, Glostrup, Denmark) and the mouse anti-human Ki-67 monoclonal antibody (Biocare Medical, Concord, CA) diluted at 1:50; both primary antibodies were incubated at room temperature (RT) for 30 min.

Techniques: Staining

Journal: Molecular Vision

Article Title: Study of the expression of CD30 in pterygia compared to healthy conjunctivas

doi:

Figure Lengend Snippet: Immunohistochemistry with the CD30 antibody of a pterygium. Representative microphotograph (100×) of a pterygium stained with CD30. The arrow indicates the strong immunoreactivity of CD30 predominantly in basal epithelium in comparison to the weak reactivity to CD30 in parabasal and superficial epithelium. The asterisk indicates perivascular immunostaining with strong immunoreactivity to CD30. The strong perivascular staining of CD30 is shown by arrowheads in the inset at higher magnification (400×).

Article Snippet: Primary antibodies were the ready-to-use mouse anti-human CD30 monoclonal antibody (Dako, Glostrup, Denmark) and the mouse anti-human Ki-67 monoclonal antibody (Biocare Medical, Concord, CA) diluted at 1:50; both primary antibodies were incubated at room temperature (RT) for 30 min.

Techniques: Immunohistochemistry, Staining, Immunostaining

Journal: Molecular Vision

Article Title: Study of the expression of CD30 in pterygia compared to healthy conjunctivas

doi:

Figure Lengend Snippet: Immunohistochemistry for CD30 and Ki-67 in serial sections of pterygium tissue. Representative microphotograph of CD30 immunopositive cells are shown in A , a serial section is shown in B for the nuclear localization of Ki-67. Note that the arrows indicate the same cells that are positive to both antigens (400×).

Article Snippet: Primary antibodies were the ready-to-use mouse anti-human CD30 monoclonal antibody (Dako, Glostrup, Denmark) and the mouse anti-human Ki-67 monoclonal antibody (Biocare Medical, Concord, CA) diluted at 1:50; both primary antibodies were incubated at room temperature (RT) for 30 min.

Techniques: Immunohistochemistry

Journal: Molecular Vision

Article Title: Study of the expression of CD30 in pterygia compared to healthy conjunctivas

doi:

Figure Lengend Snippet: Number of cells positive and negative to both CD30 and Ki-67 on basal epithelium of pterygium.

Article Snippet: Primary antibodies were the ready-to-use mouse anti-human CD30 monoclonal antibody (Dako, Glostrup, Denmark) and the mouse anti-human Ki-67 monoclonal antibody (Biocare Medical, Concord, CA) diluted at 1:50; both primary antibodies were incubated at room temperature (RT) for 30 min.

Techniques:

Journal: eLife

Article Title: Single-cell glycomics analysis by CyTOF-Lec reveals glycan features defining cells differentially susceptible to HIV

doi: 10.7554/eLife.78870

Figure Lengend Snippet:

Article Snippet: Antibody , Anti-Human CD30 (Mouse, Monoclonal) , BD Biosciences , Cat# 555827 , CyTOF (1:33).

Techniques: Recombinant, Plasmid Preparation, Software